HeartBeam has entered a strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership combines HeartBeam's patented ECG platform, which captures the heart's electrical activity from three non-coplanar dimensions, with Mount Sinai's clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring.
The collaboration will leverage longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai's clinical data resources. This combined approach aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical indications and enable broader applications in preventive cardiology, chronic disease management and remote patient monitoring.
HeartBeam's technology represents a significant advancement in cardiac monitoring capabilities. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to technology enablement, providing a strong foundation for this collaborative research initiative. Additional information about the company is available through its newsroom at https://ibn.fm/BEAT.
This collaboration has significant implications for the future of cardiac care. By combining HeartBeam's innovative 3D ECG technology with Mount Sinai's extensive clinical data and AI expertise, the partnership could accelerate the development of algorithms that enable earlier detection of cardiac conditions, more personalized treatment approaches, and improved remote monitoring capabilities. The focus on home-based data collection addresses growing needs in healthcare for solutions that extend beyond traditional clinical settings.
The development of more sophisticated AI-ECG algorithms could transform how cardiac conditions are monitored and managed, potentially reducing hospital visits, enabling earlier intervention, and improving outcomes for patients with chronic cardiac conditions. As healthcare continues to shift toward more remote and preventive approaches, technologies that enable accurate cardiac monitoring outside clinical settings become increasingly valuable. The partnership represents a convergence of technological innovation and clinical expertise that could advance the field of digital cardiology.
For more detailed information about the collaboration, readers can view the full press release at https://ibn.fm/gKzvQ. The terms of use and disclaimers applicable to this content are available at http://IBN.fm/Disclaimer. The collaboration between HeartBeam and Mount Sinai represents a significant step toward developing more sophisticated tools for cardiac monitoring that could benefit patients, healthcare providers, and the broader healthcare system through improved detection and management of cardiac conditions.
